Combined hyperthermia and re-irradiation in non-breast cancer patients: a systematic review

Purpose: This systematic literature review summarizes clinical studies and trials involving combined non-ablative hyperthermia and re-irradiation in locoregionally recurrent cancer except breast cancer. Methods: One database and one registry, MEDLINE and clinicaltrials.gov, respectively, were search...

Full description

Saved in:
Bibliographic Details
Main Authors: Kim, Ji-Young (Author) , Zschaeck, Sebastian (Author) , Debus, Jürgen (Author) , Weykamp, Fabian (Author)
Format: Article (Journal)
Language:English
Published: 25 January 2023
In: Cancers
Year: 2023, Volume: 15, Issue: 3, Pages: 1-19
ISSN:2072-6694
DOI:10.3390/cancers15030742
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers15030742
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/15/3/742
Get full text
Author Notes:Ji-Young Kim, Sebastian Zschaeck, Jürgen Debus and Fabian Weykamp
Description
Summary:Purpose: This systematic literature review summarizes clinical studies and trials involving combined non-ablative hyperthermia and re-irradiation in locoregionally recurrent cancer except breast cancer. Methods: One database and one registry, MEDLINE and clinicaltrials.gov, respectively, were searched for studies on combined non-ablative hyperthermia and re-irradiation in non-breast cancer patients. Extracted study characteristics included treatment modalities and re-irradiation dose concepts. Outcomes of interest were tumor response, survival measures, toxicity data and palliation. Within-study bias assessment included the identification of conflict of interest (COI). The final search was performed on 29 August 2022. Results: Twenty-three articles were included in the final analysis, reporting on 603 patients with eight major tumor types. Twelve articles (52%) were retrospective studies. Only one randomized trial was identified. No COI statement was declared in 11 studies. Four of the remaining twelve studies exhibited significant COI. Low study and patient numbers, high heterogeneity in treatment modalities and endpoints, as well as significant within- and across-study bias impeded the synthesis of results. Conclusion: Outside of locoregionally recurrent breast cancer, the role of combined moderate hyperthermia and re-irradiation can so far not be established. This review underscores the necessity for more clinical trials to generate higher levels of clinical evidence for combined re-irradiation and hyperthermia.
Item Description:Gesehen am 21.03.2023
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers15030742